SI2828284T1 - Virus JC nevtralizirajoča protitelesa - Google Patents

Virus JC nevtralizirajoča protitelesa

Info

Publication number
SI2828284T1
SI2828284T1 SI201331459T SI201331459T SI2828284T1 SI 2828284 T1 SI2828284 T1 SI 2828284T1 SI 201331459 T SI201331459 T SI 201331459T SI 201331459 T SI201331459 T SI 201331459T SI 2828284 T1 SI2828284 T1 SI 2828284T1
Authority
SI
Slovenia
Prior art keywords
neutralizing antibodies
jcv neutralizing
jcv
antibodies
neutralizing
Prior art date
Application number
SI201331459T
Other languages
English (en)
Inventor
Kenneth Simon
Thomas Cameron
Deping Wang
Joseph Arndt
Mia Rushe
Justin Caravella
Eric Day
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of SI2828284T1 publication Critical patent/SI2828284T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SI201331459T 2012-03-20 2013-03-15 Virus JC nevtralizirajoča protitelesa SI2828284T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613214P 2012-03-20 2012-03-20
EP13765090.9A EP2828284B1 (en) 2012-03-20 2013-03-15 Jcv neutralizing antibodies
PCT/US2013/031842 WO2013142299A1 (en) 2012-03-20 2013-03-15 Jcv neutralizing antibodies

Publications (1)

Publication Number Publication Date
SI2828284T1 true SI2828284T1 (sl) 2019-10-30

Family

ID=49223243

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201331459T SI2828284T1 (sl) 2012-03-20 2013-03-15 Virus JC nevtralizirajoča protitelesa

Country Status (15)

Country Link
US (1) US9567392B2 (sl)
EP (2) EP3575311A1 (sl)
CA (1) CA2867902C (sl)
CY (1) CY1121856T1 (sl)
DK (1) DK2828284T3 (sl)
ES (1) ES2731757T3 (sl)
HR (1) HRP20190937T1 (sl)
HU (1) HUE044838T2 (sl)
LT (1) LT2828284T (sl)
PL (1) PL2828284T3 (sl)
PT (1) PT2828284T (sl)
RS (1) RS58910B1 (sl)
SI (1) SI2828284T1 (sl)
TR (1) TR201909801T4 (sl)
WO (1) WO2013142299A1 (sl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2867910C (en) 2012-03-20 2023-09-26 Biogen Idec Ma Inc. Jcv neutralizing antibodies
PT2828284T (pt) 2012-03-20 2019-06-17 Biogen Ma Inc Jcv neutralizando anticorpos
ITTO20120570A1 (it) * 2012-06-27 2013-12-28 Pomona Ricerca Srl Anticorpo monoclonale diretto contro il virus jc
US9862760B2 (en) * 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
CN111417651B (zh) 2017-12-01 2023-09-29 诺华股份有限公司 多瘤病毒中和抗体
WO2020257633A2 (en) * 2019-06-19 2020-12-24 Icahn School Of Medicine At Mount Sinai Monoclonal antibodies against jc virus

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
JPH08507680A (ja) 1993-01-12 1996-08-20 バイオジェン インコーポレイテッド 組換え抗ｖｌａ４抗体分子
EP0682529B2 (en) 1993-02-09 2005-12-28 Biogen Idec MA, Inc. Antibody for the treatment of insulin dependent diabetes
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US7592426B2 (en) 2005-03-10 2009-09-22 Morphotek, Inc. Anti-mesothelin antibodies
CA2994756C (en) 2005-12-20 2020-10-27 Sbi Biotech Co., Ltd. Anti-ilt7 antibody
US7655417B2 (en) 2006-05-31 2010-02-02 Hanwha Chemical Corporation VCAM-1 specific monoclonal antibody
US7910702B2 (en) 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
EP2125024B1 (en) * 2007-03-23 2013-02-13 TO-BBB Holding B.V. Targeted intracellular delivery of antiviral agents
EP2167130A2 (en) 2007-07-06 2010-03-31 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
EP2307457B2 (en) * 2008-06-25 2022-06-22 Novartis AG Stable and soluble antibodies inhibiting tnf
CA2751364C (en) 2009-02-05 2017-06-20 Biogen Idec Ma Inc. Methods for the detection of jc polyoma virus
WO2010129959A1 (en) 2009-05-08 2010-11-11 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the prevention and treatment of lupus nephritis using anti-dsdna germline antibodies
EP2316481A1 (en) * 2009-10-30 2011-05-04 Biomay Ag Pharmaceutical composition for the treatment and prevention of a rhinovirus infection
PT2828284T (pt) 2012-03-20 2019-06-17 Biogen Ma Inc Jcv neutralizando anticorpos
CA2867910C (en) 2012-03-20 2023-09-26 Biogen Idec Ma Inc. Jcv neutralizing antibodies

Also Published As

Publication number Publication date
RS58910B1 (sr) 2019-08-30
EP2828284A1 (en) 2015-01-28
PT2828284T (pt) 2019-06-17
PL2828284T3 (pl) 2019-11-29
US9567392B2 (en) 2017-02-14
DK2828284T3 (da) 2019-06-11
CY1121856T1 (el) 2020-07-31
CA2867902C (en) 2023-09-26
US20150050271A1 (en) 2015-02-19
LT2828284T (lt) 2019-08-26
WO2013142299A1 (en) 2013-09-26
ES2731757T3 (es) 2019-11-18
HRP20190937T1 (hr) 2019-10-04
TR201909801T4 (tr) 2019-07-22
EP3575311A1 (en) 2019-12-04
EP2828284A4 (en) 2015-07-22
EP2828284B1 (en) 2019-05-08
CA2867902A1 (en) 2013-09-26
HUE044838T2 (hu) 2019-11-28

Similar Documents

Publication Publication Date Title
IL264558A (en) Anti–il–23p19 antibodies
HK1204627A1 (en) Anti-fcrn antibodies fcrn
HK1204571A1 (en) Protease-regulated antibodies
HK1210192A1 (en) Anti-siglec-15 antibodies siglec-15
EP2930240A4 (en) ANTI-FOLR1 ANTIBODY
SG10201608382QA (en) Anti-fgfr2 antibody
EP2828292A4 (en) JCV NEUTRALIZING ANTIBODIES
EP2826790A4 (en) GREMLIN-1 ANTIBODY
IL234883A0 (en) CDR-modified anti-siglac-15 antibody
HK1210186A1 (en) Anti-h7cr antibodies h7cr
LT2828284T (lt) Jcv neutralizuonatys antikūnai
PL2935330T3 (pl) Przeciwciała przeciw notch3
GB201220242D0 (en) Antibody
EP2848633A4 (en) ANTI-CXADR ANTIBODY
EP2811018A4 (en) ANTI-BODY ANTI-sAPPß
IL235188A0 (en) Antibodies against c-pdgf
GB201216749D0 (en) Antigen combinations
GB201200568D0 (en) Antigen combinations